肌萎缩侧索硬化中的正电子发射断层显像:面向分子病理标志物的靶向探索
本文综述了已在肌萎缩侧索硬化(ALS)中应用的放射性示踪剂,并讨论了针对ALS发病和进展相关病理过程的新型体内显像靶点。文中指出症状出现时已有超过30%的运动神经元丢失,因此需要在症状前早期阶段实现无创体内检测;[18F]-FDG近期被提出作为ALS的潜在生物标志物,而针对潜在病理分子过程的主动靶向可能揭示更多疾病信息并有助于阐明ALS的发病机制。
要点
- 症状临床显现时已有超过30%的运动神经元丢失,需在症状前早期阶段实现无创体内检测。
- 非运动体征在ALS中起重要作用,且与额颞叶痴呆(FTD)等认知障碍存在重叠。
- [18F]-FDG近期被提出作为ALS的潜在生物标志物,针对潜在病理分子过程的主动靶向可能揭示更多疾病信息。
核心结论
- 针对ALS潜在病理分子过程的放射性示踪剂主动靶向可能揭示更多有价值的疾病信息,并可能有助于阐明ALS的发病机制。
研究设计与样本
- 综述,概述已在ALS中应用的放射性示踪剂并讨论ALS发病和进展相关病理过程的新型体内显像靶点。
主要发现
- 症状临床显现时已有超过30%的运动神经元丢失。
- 非运动体征在ALS中起重要作用,且与额颞叶痴呆(FTD)等认知障碍存在重叠。
- [18F]-FDG近期被提出作为ALS的潜在生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the past decades, extensive efforts have been made to expand the knowledge of amyotrophic lateral sclerosis (ALS). However, clinical translation of this research, in terms of earlier diagnosis and improved therapy, remains challenging. Since more than 30% of motor neurons are lost when symptoms become clinically apparent, techniques allowing non-invasive, in vivo detection of motor neuron degeneration are needed in the early, pre-symptomatic disease stage. Furthermore, it has become apparent that non-motor signs play an important role in the disease and there is an overlap with cognitive disorders, such as frontotemporal dementia (FTD). Radionuclide imaging, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), form an attractive approach to quantitatively monitor the ongoing neurodegenerative processes. Although [18F]-FDG has been recently proposed as a potential biomarker for ALS, active targeting of the underlying pathologic molecular processes is likely to unravel further valuable disease information and may help to decipher the pathogenesis of ALS. In this review, we provide an overview of radiotracers that have already been applied in ALS and discuss possible novel targets for in vivo imaging of various pathogenic processes underlying ALS onset and progression.
引用
- Willekens SM, Van Weehaeghe D, Van Damme P, et al. Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks. Eur J Nucl Med Mol Imaging. 2016. PMID: 27933416. doi:10.1007/s00259-016-3587-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。